Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMAK85L)

Drug Name
Natalizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Approved [1]
Multiple sclerosis 8A40 Approved [1]
Cross-matching ID
TTD Drug ID
DMAK85L

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-4 (ITGA4) TT4BT06 ITA4_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Integrin alpha-4 (ITGA4) DTT ITGA4 4.154 4.684 4.536 4.392
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Crohn disease
ICD Disease Classification DD70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Integrin alpha-4 (ITGA4) DTT ITGA4 9.70E-14 1.52 7.72
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website.
2 Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.